Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Breakthrough drugs in the treatment of hypertension-related disease.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

Same author

Fibroblast activation protein protects the ischemic brain through regulation of post-ischemic inflammation.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026

Same author

The blood pressure-lowering effect of an anti-soluble epoxide hydrolase vaccine in angiotensin II-induced hypertension in mice.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

Same author

A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice.

Anticancer research·2026

Same author

Changes in blood pressure following the relocation of individuals to well-insulated and well-ventilated apartments building.

Hypertension research : official journal of the Japanese Society of Hypertension·2026

Same author

Effect of Nicotinamide Mononucleotide on Retinal Thickness of Older Patients With Diabetes Mellitus: A Placebo-Controlled, Double-Blind Study.

Geriatrics & gerontology international·2026

Search research articles

Related Experiment Video

Updated: May 11, 2026

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Recent progress in therapeutic angiogenesis.

Hironori Nakagami¹, Ryuichi Morishita

¹Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita 565-0871, Japan; ; Division of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita 565-0871, Japan.

International Journal of Biomedical Science : IJBS

|May 16, 2013

Summary

Therapeutic angiogenesis using bone marrow cells or gene therapy shows promise for treating ischemic diseases like coronary artery disease and peripheral arterial disease by promoting new blood vessel growth.

Keywords:

angiogenesis bone marrow mononuclear cell endothelial progenitor cell hepatocyte growth factor

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

Related Experiment Videos

Last Updated: May 11, 2026

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Preclinical Model of Hind Limb Ischemia in Diabetic Rabbits

Published on: June 2, 2019

Area of Science:

Cardiovascular Medicine
Regenerative Medicine
Vascular Biology

Background:

Coronary artery disease (CAD) and peripheral arterial disease (PAD) involve acute vessel occlusion due to atherosclerosis.
Therapeutic angiogenesis aims to restore blood flow in ischemic tissues by stimulating new vessel formation.

Purpose of the Study:

To review current therapeutic angiogenesis strategies for ischemic cardiovascular and peripheral arterial diseases.
To evaluate the potential of bone marrow mononuclear cells (BMMNCs) and endothelial progenitor cells (EPCs) in promoting neovascularization.

Main Methods:

Review of clinical trials involving autologous transplantation of BMMNCs or EPCs.
Analysis of gene therapy approaches, specifically using hepatocyte growth factor (HGF).
Exploration of proposed mechanisms for bone marrow cell regeneration.

Main Results:

Pilot studies indicate that BMMNC and EPC transplantation can improve blood flow and function in ischemic limbs and hearts.
Gene therapy with HGF shows comparable improvements in PAD, potentially offering a less invasive approach.
The regenerative potential of bone marrow cells is attributed to transdifferentiation, cytokine release, stem cell stimulation, and cell fusion.

Conclusions:

Autologous cell transplantation and HGF gene therapy represent promising therapeutic strategies for CAD and PAD.
Further research is needed to identify optimal angiogenic factors and specific progenitor cells for bone marrow cell therapy.
Developing safe and effective strategies is crucial for achieving therapeutic angiogenesis in patients with ischemic diseases.